Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06673966 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia

Study acronym: SZIM
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 1, 2026 to Feb 1, 2027v7
  2. Primary endpoints: 5 to 7
    • Eligibility criteria shortened, about 17 words
    • Secondary endpoints: 11 to 9
    v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2024 to Jan 10, 2025
    v5
  4. Secondary endpoints revised (11)v4
  5. Secondary endpoints: 9 to 11v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Schizophrenia is a severe mental illness that seriously affects the health and functioning of patients. Previous studies have found immunoinflammatory abnormalities in the blood, cerebrospinal fluid, central nervous system, and neuroimaging of people with schizophrenia, along with therapeutic effects of anti-inflammatory drugs on schizophrenia. These evidences suggest a close relationship between schizophrenia and immunity and inflammation. Therefore, we consider that the state of immune inflammation is a potential subtype classification basis for schizophrenia, and hypothesize that immune classification based on peripheral-central multidimensional data is related to patient's response to medication and cognition.
Trial Details
NCT Number NCT06673966
Lead Sponsor Central South University
Conditions
(from sponsor)		 Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders
Related terms Inflammation, Mental Disorders, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov